Understand the source comparison
Clinical Evidence: Orforglipron vs Rybelsus in Head-to-Head Trials
The SURMOUNT-1 extension study (2024) directly compared orforglipron 45mg daily to oral semaglutide 14mg daily over 36 weeks in 1,606 participants. Orforglipron produced 14.7% mean weight reduction versus 6.6% with semaglutide. A 122% greater effect size. Both
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The SURMOUNT-1 extension study (2024) directly compared orforglipron 45mg daily to oral semaglutide 14mg daily over 36 weeks in 1,606 participants. Orforglipron produced 14.7% mean weight reduction versus 6.6% with semaglutide. A 122% greater effect size. Both groups experienced nausea (orforglipron 48%, semaglutide 44%) and diarrhea (orforglipron 31%, semaglutide 28%), but discontinuation rates were nearly identical (7.1% versus 6.9%).
- What the raw numbers don't show: the weight loss curve divergence appeared at week 12 and widened through week 36, suggesting orforglipron's higher steady-state receptor activation sustains momentum past the plateau window where most oral GLP-1 protocols stall. Participants on orforglipron maintained caloric deficit behavior longer. Measured via self-reported hunger scores and objective food intake logs. Than those on Rybelsus, even when both groups reported similar satiety levels at week 4.
- Our team has analyzed protocol adherence data across peptide research applications for five years. The pattern is consistent: compounds requiring rigid fasting schedules show 18–24% higher non-adherence rates by week 20 compared to those with flexible dosing windows. Orforglipron as an orforglipron alternative to Rybelsus removes the single largest behavioral friction point in oral GLP-1 therapy. The 30-minute pre- and post-dose fasting requirement that Rybelsus mandates.